» Articles » PMID: 22083905

Osteoporosis Patient Treatment Satisfaction Questionnaire in Postmenopausal Women Intermittently Treated with Oral Bisphosphonates: the BRAVO Study

Overview
Specialty Endocrinology
Date 2011 Nov 16
PMID 22083905
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q) is a psychometric measure of patient satisfaction with bisphosphonate treatment for osteoporosis. The study was a multicenter, nationwide, cross-sectional, patient-reported outcome study conducted to evaluate treatment satisfaction and quality of life using the OPSAT-Q in patients receiving oral bisphosphonate therapy. This study enrolled postmenopausal women from 43 hospitals and 112 clinics who had intermittently taken oral bisphosphonates for treatment of osteoporosis. 4,220 postmenopausal Korean women with a mean age of 65.3 years and a mean body mass index of 22.9 kg/m(2) participated in the study. All items within each subscale domain were more highly correlated with their hypothesized subscale domain relative to the other subscale domains, and all 16 items were significantly correlated with an overall composite satisfaction score (CSS). All scores showed acceptable internal consistency reliability (Cronbach's alpha >0.70, range 0.88-0.91). Comparisons of OPSAT-Q scores were made between selective subgroups of participants: monthly versus weekly administration, years of taking bisphosphonates, smoking habitus, acid-related medication and comorbid conditions. Mean OPSAT-Q subscale domains and CSS were higher for users of monthly bisphosphonates, with shorter duration, non-smokers, and non-users of acid-related medication. Mean OPSAT-Q subscale domain scores of side-effects were high for absence of comorbid conditions. The OPSAT-Q demonstrated acceptable measurement properties, including validity and reliability of subscale domains and CSS, in oriental women with postmenopausal osteoporosis. Postmenopausal women intermittently using oral bisphosphonate therapy reported increased satisfaction with monthly administration, with shorter duration, non-smokers, non-users of acid-related medication, and an absence of comorbid conditions.

Citing Articles

Influence of gastrointestinal events on treatment of osteoporosis in Asia-Pacific women: Perspectives from physicians in the MUSIC OS-AP study.

Modi A, Ebeling P, Lee M, Min Y, Mithal A, Yang X Bone Rep. 2017; 7:108-113.

PMID: 29062864 PMC: 5650647. DOI: 10.1016/j.bonr.2017.09.003.


Impact of gastrointestinal events on patient-reported outcomes in Asia-Pacific women with osteoporosis: baseline results of the MUSIC OS-AP study.

Modi A, Ebeling P, Lee M, Min Y, Mithal A, Yang X Arch Osteoporos. 2017; 12(1):65.

PMID: 28718004 PMC: 5514202. DOI: 10.1007/s11657-017-0350-3.


Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study in the Asia-Pacific Region (MUSIC OS-AP): Design of a multinational, prospective, observational study examining the impact of gastrointestinal events on....

Modi A, Ebeling P, Lee M, Min Y, Mithal A, Yang X Bone Rep. 2017; 3:61-66.

PMID: 28377968 PMC: 5365206. DOI: 10.1016/j.bonr.2015.09.002.


Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary.

Hwang J, Chan D, Chen J, Cheng T, Wu C, Soong Y J Bone Miner Metab. 2013; 32(1):10-6.

PMID: 24068612 DOI: 10.1007/s00774-013-0495-0.

References
1.
Flood E, Beusterien K, Green H, Shikiar R, Baran R, Amonkar M . Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes. 2006; 4:42. PMC: 1550233. DOI: 10.1186/1477-7525-4-42. View

2.
Rietbrock S, Olson M, van Staa T . The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM. 2008; 102(1):35-42. DOI: 10.1093/qjmed/hcn130. View

3.
Carr A, Thompson P, Cooper C . Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int. 2006; 17(11):1638-44. DOI: 10.1007/s00198-006-0166-2. View

4.
Cramer J, Gold D, Silverman S, Lewiecki E . A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007; 18(8):1023-31. DOI: 10.1007/s00198-006-0322-8. View

5.
Ohbayashi H . [Examination of beneficial effects of risedronate in improving quality of life during long-term treatment of primary osteoporosis]. Nihon Rinsho. 2009; 67(1):206-12. View